Publicacions en col·laboració amb investigadors/es de Policlinico Umberto I (17)

2024

  1. Evaluation of a quality improvement intervention to reduce anastomotic leak following right colectomy (EAGLE): pragmatic, batched stepped-wedge, cluster-randomized trial in 64 countries

    British Journal of Surgery, Vol. 111, Núm. 1

2023

  1. Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial

    American Journal of Cardiology, Vol. 208, pp. 16-24

  2. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 20, pp. 2514-2524

  3. Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 9, Núm. 4, pp. 328-336

2022

  1. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index

    JACC: Cardiovascular Interventions, Vol. 15, Núm. 19, pp. 1948-1960

  2. Thalassaemia is paradoxically associated with a reduced risk of in-hospital complications and mortality in COVID-19: Data from an international registry

    Journal of Cellular and Molecular Medicine, Vol. 26, Núm. 9, pp. 2520-2528

  3. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy

    JACC: Cardiovascular Interventions, Vol. 15, Núm. 3, pp. 282-293

2021

  1. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI

    JACC: Cardiovascular Interventions, Vol. 14, Núm. 13, pp. 1434-1446

  2. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR

    European Heart Journal, Vol. 42, Núm. 45, pp. 4624-4634

  3. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD

    European Heart Journal, Vol. 42, Núm. 45, pp. 4683-4693

2019

  1. Ticagrelor with or without aspirin in high-risk patients after PCI

    New England Journal of Medicine, Vol. 381, Núm. 21, pp. 2032-2042

2017

  1. Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort

    Clinical Infectious Diseases, Vol. 65, Núm. 10, pp. 1615-1623

  2. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study

    International Journal of Antimicrobial Agents, Vol. 50, Núm. 5, pp. 664-672

2016

  1. A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae

    Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 7, pp. 4159-4169

  2. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: A multinational pre-registered cohort study

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 6, pp. 1672-1680

2013

  1. Comparative effects of teriparatide and risedronate in glucocorticoid- induced osteoporosis in men: 18-month results of the EuroGIOPs trial

    Journal of Bone and Mineral Research, Vol. 28, Núm. 6, pp. 1355-1368

  2. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis

    Osteoporosis International, Vol. 24, Núm. 12, pp. 2971-2981